Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Dec. 15 '25)

 


    Biochem Biophys Res Commun

  1. HU J, Li J, You W, Liu L, et al
    Disruption of the local vRNA structure at the end of HA encoding region interferes with the selective packaging of influenza A virus genome.
    Biochem Biophys Res Commun. 2025;795:153082.
    PubMed         Abstract available

  2. BANGARU MLY, Raghavendra NK
    Helix alpha1 of human ACE2 mimics dsDNA and Spike of SARS-CoV-2 binds DNA.
    Biochem Biophys Res Commun. 2025;793:153020.
    PubMed         Abstract available


    Cell

  3. WASDIN PT, Johnson NV, Janke AK, Held S, et al
    Generation of antigen-specific paired-chain antibodies using large language models.
    Cell. 2025;188:7206-7221.
    PubMed         Abstract available

  4. YAN L, Huang Y, Liu Y, Ge J, et al
    Structural basis for the concurrence of template recycling and RNA capping in SARS-CoV-2.
    Cell. 2025;188:7194-7205.
    PubMed         Abstract available


    Epidemiol Infect

  5. ASPLIN P, Fyles M, Kennedy J, Ward T, et al
    Evaluating Google Trends as a proxy for symptom incidence: insights from the winter COVID-19 infection study in England 2023/24.
    Epidemiol Infect. 2025;153:e136.
    PubMed         Abstract available

  6. MUNCH PK, Hansen CH, Moller FT, Norgaard SK, et al
    COVIDmeter - a questionnaire-based symptom monitoring system for the surveillance of COVID-19 in Denmark, 2020-2023.
    Epidemiol Infect. 2025;153:e134.
    PubMed         Abstract available


    J Epidemiol Community Health

  7. ZHAO M, Yang L, Cheng P, Schwebel D, et al
    Helmet use among cyclists and motorcyclists involved in media-reported road traffic crashes after implementation of the national 'One Helmet, One Belt' campaign in China.
    J Epidemiol Community Health. 2025;80:35-40.
    PubMed         Abstract available


    J Exp Med

  8. ZHANG Q, Conrad TS, Moncada-Velez M, Jiang K, et al
    Autoantibodies neutralizing type I IFNs in a fatal case of H5N1 avian influenza.
    J Exp Med. 2026;223:e20251962.
    PubMed         Abstract available


    J Gen Virol

  9. VAN DIEMEN PM, Ramsay AM, Everett HE, Hurley S, et al
    Experimental infection of alpacas (Vicugna pacos) with influenza C or D viruses results in subclinical upper respiratory tract disease.
    J Gen Virol. 2025;106.
    PubMed         Abstract available


    J Immunol

  10. ALBE JR, Chaudhary A, Khanna A, Weinstein K, et al
    Divergent effects of a Treg-selective IL-2 mutein on influenza-specific T cell responses.
    J Immunol. 2025 Dec 10:vkaf297. doi: 10.1093.
    PubMed         Abstract available


    J Infect

  11. KITANO T, Tsuzuki S, Fukuda H, Yoshida S, et al
    Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database.
    J Infect. 2025;91:106652.
    PubMed         Abstract available


    J Infect Dis

  12. DAULAGALA P, Leung YWY, Luk LLH, Ho F, et al
    Anti-neuraminidase antibody responses in older adults after consecutive vaccinations with enhanced influenza vaccines: a randomized controlled trial.
    J Infect Dis. 2025 Dec 8:jiaf616. doi: 10.1093.
    PubMed         Abstract available


    J Neurosurg Pediatr

  13. GELMAN K, Fletcher D, Li H, Wen S, et al
    The use of telehealth in pediatric neurosurgery for rural patients of Appalachia.
    J Neurosurg Pediatr. 2025;36:755-763.
    PubMed         Abstract available


    J Virol

  14. KAR J, Hirohama M, Nakayama K, Lee S, et al
    Microtubule detyrosination links inflammasome activation to apoptotic cell death in macrophages upon influenza A virus infection.
    J Virol. 2025 Dec 9:e0184725. doi: 10.1128/jvi.01847.
    PubMed         Abstract available


    J Virol Methods

  15. JAASKELAINEN AE, Pitkaranta A, Haaramo A, Nokso-Koivisto J, et al
    Saliva samples in SARS-Cov-2 virus detection compared to the nasopharyngeal RT-PCR findings in individuals with suspected COVID-19 infection.
    J Virol Methods. 2026;340:115295.
    PubMed         Abstract available

  16. MORWITZER MJ, Zheng YY, Friberg H, Currier JR, et al
    A split GFP approach to assay SARS-CoV-2 spike-dependent cell fusion.
    J Virol Methods. 2026;340:115296.
    PubMed         Abstract available

  17. THIBAUT J, Gambaro F, Geenen C, Hong SL, et al
    A novel methodology for assessing contact tracing precision: Phylogenetic validation of a contact tracing program for COVID-19 in Belgium.
    J Virol Methods. 2026;340:115279.
    PubMed         Abstract available

  18. GOSWAMI P, Chatterjee D, Ghosh S, Paira K, et al
    Ultra-diluted Bryonia alba extract modulates HMOX-1 gene expression to attenuate the pathogenetic effect of SARS-CoV-2 spike protein RBD antigen.
    J Virol Methods. 2026;340:115274.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  19. IRVING SA, Rowley EAK, Chickery S, Natarajan K, et al
    Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:607-614.
    PubMed         Abstract available

  20. ZAMBRANO LD, Simeone RM, Newhams MM, Payne AB, et al
    Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:580-588.
    PubMed         Abstract available


    N Engl J Med

  21. NEUZIL KM
    Current and Emerging Approaches to Evaluating Influenza Vaccine Performance.
    N Engl J Med. 2025;393:2361-2362.
    PubMed        


    PLoS Biol

  22. STERTZ S, Karakus U
    A new path to spillover: MHC-II entry of influenza A viruses.
    PLoS Biol. 2025;23:e3003550.
    PubMed         Abstract available


    PLoS Comput Biol

  23. MORRIS DJ, Kennedy L, Black AJ
    Random time-shift approximation enables hierarchical Bayesian inference of mechanistic within-host viral dynamics models on large datasets.
    PLoS Comput Biol. 2025;21:e1013775.
    PubMed         Abstract available

  24. LEFEBVRE A, Marechal V, Gloaguen A, Lambert A, et al
    Unsupervised detection and fitness estimation of emerging SARS-CoV-2 variants: Application to wastewater samples (ANRS0160).
    PLoS Comput Biol. 2025;21:e1013749.
    PubMed         Abstract available

  25. PINERO S, Li X, Liu L, Li J, et al
    Integrative multi-omics framework for causal gene discovery in Long COVID.
    PLoS Comput Biol. 2025;21:e1013725.
    PubMed         Abstract available


    PLoS One

  26. PICARD-MEYER E, Wasniewski M, Boue F, Torres-Maravilla E, et al
    Lung infection in orally inoculated SARS-CoV-2 hamsters.
    PLoS One. 2025;20:e0337915.
    PubMed         Abstract available

  27. HUSSEIN M, Gebreal A, Naeem A, AboElela AM, et al
    Cross-national disparities in healthcare workers' perceptions: Examining fear of infection and confidence in the received COVID-19 vaccines amid emerging variants.
    PLoS One. 2025;20:e0318788.
    PubMed         Abstract available

  28. LU X, Duan Y
    Channels and countermeasures of the COVID-19 pandemic's impact on urban economic resilience: Lessons from China.
    PLoS One. 2025;20:e0338499.
    PubMed         Abstract available

  29. CAO T, Pan W, Liang Z, Quan J, et al
    Investigation of the effect and mechanisms of moxa smoke in the treatment of Influenza A Virus (IAV) infection.
    PLoS One. 2025;20:e0337906.
    PubMed         Abstract available

  30. SMIT PW, Man P, Brand H, Breijer S, et al
    Comparative evaluation of five rapid PCR platforms for respiratory virus detection.
    PLoS One. 2025;20:e0338716.
    PubMed         Abstract available

  31. ABBASIZANJANI H, Bedston S, Akbari A
    Creating a Research-Ready Data Asset version of primary care data for Wales and investigating the impact of COVID-19 on utilisation of primary care services.
    PLoS One. 2025;20:e0338652.
    PubMed         Abstract available

  32. YANG Y, Liang R, Luo Y, Zhu D, et al
    Investigation on the knowledge-attitude-practice of medical students in controlling emerging infectious diseases: A case study of COVID-19.
    PLoS One. 2025;20:e0338708.
    PubMed         Abstract available

  33. JANKOWSKI JM, Sik K, Job V
    The relationship between lay beliefs about the world and pandemic-related beliefs, attitudes, and behaviors.
    PLoS One. 2025;20:e0338367.
    PubMed         Abstract available

  34. SADEH S, Ghaemi A, Soleimani NA, Moghbeli M, et al
    Designing influenza virus-derived cell-penetrating peptides for antigen delivery: Integrating uptake efficiency, safety, and receptor targeting.
    PLoS One. 2025;20:e0338028.
    PubMed         Abstract available

  35. TUFON KA, Foumene TP, Esembeson M, Bolimo AF, et al
    Trends and factors associated with pneumonia mortality at Buea Regional Hospital in Cameroon from 2020 to 2023.
    PLoS One. 2025;20:e0313234.
    PubMed         Abstract available

  36. MARINDA E, Naidoo Y, Magampa M, Pindo A, et al
    Changes in quality of life over time through the lens of young people aged 18-24 in 2016 in Gauteng Province of South Africa.
    PLoS One. 2025;20:e0338312.
    PubMed         Abstract available

  37. CARNEY-KNISELY G, Pek J, Ferketich AK, Padamsee TJ, et al
    Depression and anxiety mediate the relationship between COVID-19 stay-at-home orders and tobacco and marijuana use.
    PLoS One. 2025;20:e0337996.
    PubMed         Abstract available

  38. CONTI S, Pariza P, Wolters A
    A synthetic control evaluation of the use of pulse oximeters in response to the COVID-19 pandemic in England.
    PLoS One. 2025;20:e0337617.
    PubMed         Abstract available

  39. BEGAY RL, Brown HE, Sanderson PR, Harris RB, et al
    Dine traditional medicine use and wellbeing among navajo adults during the COVID-19 pandemic: A cross-sectional study.
    PLoS One. 2025;20:e0337427.
    PubMed         Abstract available

  40. COUDERT JF, Dadachova E, Maignant G, Jonathan S, et al
    Radon exposure and COVID-19 mortality in pre-vaccination period: What links might exist?
    PLoS One. 2025;20:e0337320.
    PubMed         Abstract available

  41. COSTA T
    The impossible confounder: Quantifying the limits of alternative explanations for COVID-19 vaccine effectiveness.
    PLoS One. 2025;20:e0336063.
    PubMed         Abstract available

  42. DIAO YC, Lou MF
    Development and validation of the healthcare provider and family bidirectional digital communication scale.
    PLoS One. 2025;20:e0338410.
    PubMed         Abstract available

  43. GEORGE NA, Bradford L, Hinz A, El Kadi M, et al
    SARS-CoV-2 detection is independent of microbiome composition on surfaces in a major Ontario hospital.
    PLoS One. 2025;20:e0326403.
    PubMed         Abstract available

  44. HUUSKO M, Vuohijoki A, Ristolainen L, Leppilahti J, et al
    Implementation and staff perceptions of a quality assurance system in a finnish private hospital during the COVID-19 Pandemic: A qualitative study.
    PLoS One. 2025;20:e0327271.
    PubMed         Abstract available

  45. PARUBETS S, Naito H
    Predicting economic activity using atmospheric nitrogen dioxide (NO2) satellite data: Evidence from local economic indicators in Japan.
    PLoS One. 2025;20:e0337901.
    PubMed         Abstract available

  46. FUHRMANN V, Tyczynski B, Perez Ruiz de Garibay A, Bingold TM, et al
    The Advanced Organ Support (ADVOS) hemodialysis system fulfills its intended purpose: Analysis of data from 282 patients from the Registry on Extracorporeal Multiple Organ Support (EMOS).
    PLoS One. 2025;20:e0318917.
    PubMed         Abstract available


    Vaccine

  47. CASWELL C, Pullenayegum E, Singh P, Ward BJ, et al
    Sex-differences in influenza vaccine efficacy and immunogenicity among Canadian Hutterite children.
    Vaccine. 2025;72:128102.
    PubMed         Abstract available

  48. WALTER EB, Schlaudecker EP, Talaat KR, Rountree W, et al
    Immunogenicity of mRNA COVID-19 vaccine with either simultaneous or sequentially administered inactivated influenza vaccines: a randomized clinical trial.
    Vaccine. 2025;72:128072.
    PubMed         Abstract available

  49. SONG JY, Cheong HJ
    Understanding the low effectiveness of influenza vaccines in older adults of South Korea: an exploration of contributing factors.
    Vaccine. 2025;71:128076.
    PubMed         Abstract available

  50. MEYER AC, Braegelmann K, Orozco-Ruiz X, Kruppert S, et al
    Comparing uptake of high-dose and standard-dose influenza vaccination at the practice and patient level in Germany.
    Vaccine. 2025;71:128075.
    PubMed         Abstract available

  51. ASKAR M, Adel K, Batke M, Chi Y, et al
    Population effects of influenza vaccination in children and adolescents: Systematic review.
    Vaccine. 2025;71:128040.
    PubMed         Abstract available

  52. RICHARDSON RA, Moon C, Sands CM, Nelson R, et al
    Generation of a shelf-stable, broadly-reactive influenza vaccine formulated with TLR4, TLR7/8, or TLR9 stimulating adjuvants.
    Vaccine. 2025;72:128028.
    PubMed         Abstract available

  53. REEVES C, Miura SST, Chappell AR, Banaag A, et al
    Trends in influenza vaccination uptake in a universally insured population in the united states, 2017-2023.
    Vaccine. 2025;71:128052.
    PubMed         Abstract available

  54. ABBAD A, Lerman B, Ehrenhaus J, Ojeda DS, et al
    Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naive and convalescent populations.
    Vaccine. 2025;70:128018.
    PubMed         Abstract available

  55. KIM SH, Kang MG, Jang JG, Kim Y, et al
    Severe COVID-19, vaccination, and mortality among individuals with asthma: A Nationwide population-based cohort study.
    Vaccine. 2025;70:128017.
    PubMed         Abstract available

  56. HAMMOUD M, Smith AKJ, Sachs O, Bavinton BR, et al
    Drivers, barriers, and implications of mpox vaccine uptake in Australia among gay, bisexual, and other men who have sex with men: results from a prospective observational mixed-methods study (2022-2024).
    Vaccine. 2025;70:128041.
    PubMed         Abstract available

  57. LE TOURNEAU N, Sharma A, Pry JM, Haambokoma M, et al
    Drivers of decision-making for future adult vaccines: a best-worst scaling among community members and health care workers in Zambia.
    Vaccine. 2025;70:128003.
    PubMed         Abstract available

  58. DEV AS, Broos HC, Llabre MM, Saab PG, et al
    Examining the independent and interactive roles of intolerance of uncertainty in vaccination intent.
    Vaccine. 2025;70:128008.
    PubMed         Abstract available

  59. HUANG O, Tan BF, Lu CY
    Taiwanese parental perspectives on RSV: knowledge, risks, and acceptance toward immunization.
    Vaccine. 2026;70:128005.
    PubMed         Abstract available

  60. PICHE-RENAUD PP, Buchan CA, Burton C, Chapdelaine H, et al
    Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study.
    Vaccine. 2025;70:128016.
    PubMed         Abstract available

  61. CHAU SL, Hung IFN, Luk TT, Chan SSC, et al
    The impacts of long COVID and booster doses of post-infection vaccination among hospital-discharged COVID-19 survivors in Hong Kong: A retrospective observational study.
    Vaccine. 2025;70:128022.
    PubMed         Abstract available

  62. CHAZARIN B, Bhat AS, Sundararaman N, Liu Y, et al
    Longitudinal proteomic and autoantibody signatures after mRNA vaccination in healthy individuals.
    Vaccine. 2025;70:127888.
    PubMed         Abstract available

  63. VAHABI MM, Ketentzi S, Kahraman U, Erdem HA, et al
    A single center's 25-year experience with hepatitis B and pneumoccocal vaccines in heart transplant patients: the impact of the COVID-19 pandemic.
    Vaccine. 2025;70:128023.
    PubMed         Abstract available

  64. VANASSE LT, Safdar B, Self WH, Zhu Y, et al
    Comparison of immunization information systems, electronic medical records, and self-report to ascertain RSV vaccination status among US adults aged >/=60 years, 2023-2024.
    Vaccine. 2025;69:127946.
    PubMed         Abstract available

  65. LASRADO N, Rossler A, McConnell I, Molloy K, et al
    Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants.
    Vaccine. 2025;69:127997.
    PubMed         Abstract available

  66. SCHUH HB, Delamater P, Proveaux TM, Dudley MZ, et al
    In a shifting policy era: California provider knowledge and practice of medical exemption laws during the COVID-19 pandemic.
    Vaccine. 2026;69:127993.
    PubMed         Abstract available

  67. CRAMER EY, Dada AO, Onofrey S, Pearlman J, et al
    Population-based serosurveys for SARS-CoV-2 transmission 2021-2022, Massachusetts USA.
    Vaccine. 2026;69:127952.
    PubMed         Abstract available

  68. ILBOUDO DP, Simpore A, Sawadogo J, Ouattara AK, et al
    Acceptance, hesitancy, and ethical challenges of the COVID-19 vaccine in sub-Saharan Africa: a systematic review and meta-analysis.
    Vaccine. 2025;69:127966.
    PubMed         Abstract available

  69. MARTINEZ-PEREZ A, Galvez RI, Grifoni A, Sette A, et al
    Impact of the bivalent COVID-19 booster on spike-specific t cell responses.
    Vaccine. 2026;69:127995.
    PubMed         Abstract available

  70. RAUPACH J, Housria Y, Hein S, Schnierle B, et al
    Comparative analysis of a flexible novel vaccine platform based on cell permeable chimeric HBV capsids for mucosal vaccination.
    Vaccine. 2025;69:127987.
    PubMed         Abstract available

  71. CHAPMAN S, Christodoulaki ME, Davey SA, Gaffiero D, et al
    Understanding vaccine hesitancy: The role of fear and message framing in COVID-19 vaccination intention in adults in the UK.
    Vaccine. 2025;69:127999.
    PubMed         Abstract available

  72. LEDDERER L, Nielsen KH, Skodborg L, Fage-Butler A, et al
    Public trust and mistrust of COVID-19 vaccines: A systematic meta-narrative review.
    Vaccine. 2025;69:127947.
    PubMed         Abstract available

  73. GRASSI CM, Feng J, Wahid R, Kandinov B, et al
    Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.
    Vaccine. 2025;69:127960.
    PubMed         Abstract available

  74. RANA MM, Haydel B, Carrara G, Gleason C, et al
    Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV.
    Vaccine. 2025;69:127969.
    PubMed         Abstract available


    Virology

  75. BRICE DC, Andreev K, Miller L, Patton C, et al
    Immunogenicity and efficacy of commercial poultry avian influenza vaccines against HPAI A(H5N1) clade 2.3.4.4b viruses in Mexico.
    Virology. 2025;615:110765.
    PubMed         Abstract available


    Virus Res

  76. LUO L, Lv J
    Stochastic mutation as a mechanism for the emergence of SARS-CoV-2 new variants.
    Virus Res. 2025;362:199667.
    PubMed         Abstract available

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...